A Single-site Postmarket Retrospective Chart Review of Subdermal Coagulation Procedures with Renuvion
Doolabh V.
Retrospective Study, published in Plast Reconstr Surg Glob Open (2019) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Retrospective Study
- Journal
- Plast Reconstr Surg Glob Open (2019)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 31942297
- PMCID
- PMC6908349
- DOI
- 10.1097/gox.0000000000002502
- Citations
- 7
Abstract (original English)
Although tumescent liposuction provides debulking of body areas with excess subcutaneous fat and concurrent skin laxity, the ability to shrink and redrape the skin and soft tissue for added definition has remained an elusive goal. Many modalities employed to facilitate fat removal utilizing light energy, ultrasonic energy, or radiofrequency energy have provided modest skin shrinkage. Apyx Medical's (formerly Bovie Medical) Renuvion (previously branded as J-Plasma) has Food and Drug Administration clearance for the cutting, coagulation, and ablation of soft tissue. The objective of this retrospective chart review was to collect safety and procedural information for patients who have previously undergone liposuction with which Renuvion was used as a tool for subdermal coagulation. All procedures occurred before August 2018. Thirty-two patients were identified (3 male and 29 female). The mean follow-up was 6 months (range, 3-8 months). None of the patients required a revision or secondary procedure suggesting 100% of patients had acceptable final outcomes. No device-related adverse events or complications were noted, suggesting that within this data set, Renuvion's unique cool helium plasma technology can safely be used for skin contraction with or without tumescent liposuction or supplemental modalities used to facilitate fat removal that may otherwise contribute to the skin cont
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Without an adequate control group, treatment effects cannot be separated from other factors.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.